Asia Pacific RNAi Therapeutics Market Analysis and Opportunities by 2027

Asia Pacific RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)), Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Others), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others), and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals) and Geography

Report Date : Oct 2020
Report Code : TIPRE00015147

Category : Life Sciences
Status : Published

Available Report Formats :
No. of Pages : 133

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is estimated to grow at a CAGR of 9.3% from 2020 to 2027.

Growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Asia Pacific are the key factors driving the growth of RNAi therapeutics. However, high cost of RNAi therapies is the major factor hindering the market growth in Asia Pacific.

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the Asia Pacific RNAi Therapeutics market during the forecast period.

Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders, such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in June 2020, OliX Pharmaceuticals signed an agreement with LGC Biosearch technologies to accelerate production of asymmetric siRNA for the treatment of sub-retinal fibrosis and wet macular degeneration. Also, NantVentures made a private investment in public Australia based biotech Benitec Biopharma. Furthermore, Benitech and NantVentures, with the help of NantWorks, plan to begin an oncology-focused R&D collaboration with clinical development and preclinical evaluation that is to be led by Benitec. Moreover, in July 2018, Axovant Sciences signed a gene therapy licensing and development deal with Benitec Biopharma. As part of the deal, Axovant Sciences made an upfront payment of US$ 10 million to Benitec, which is also eligible for additional payments based on regulatory, development, and commercial sales milestones. Such investments help biotech and pharma companies not only launch new products but also increase number of approved products. The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.

Countries in Asia Pacific are severely affected by the COVID-19 outbreak. Several companies operating in this region are developing therapies for COVID-19. South Korea based OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi), announced that it would leverage previous preclinical research for developing siRNA therapeutics in treating respiratory illnesses to investigate a path forward for developing a COVID-19 therapy. Such continuous developments of RNAi therapies in Asia Pacific are likely to propel the market growth in this region.

Rest of Asia Pacific RNAi Therapeutics Market, Revenue, and Forecast to 2027 (US$ Million)

Inquire for Discount

Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Request discounts available for Start-Ups & Universities

Asia Pacific RNAi Therapeutics Market Segmentation

By Molecule Type

Small Interfering RNAs (siRNA)
MicroRNA (miRNA)

By Route of Administration

Pulmonary Delivery
Intravenous Injections
Intradermal Injections
Intraperitoneal Injections
Others

By Application

Oncology
Cardiovascular
Respiratory Disorders
Renal Diseases
Genetic Disorders
Neurodegenerative Disorders
Infectious Diseases
Others

By End User

Research and Academic Laboratories
Hospitals
Diagnostic Laboratories

By Country

Japan
China
India
South Korea
Australia

Company Profiles

Benitec Biopharma
GlaxoSmithKline plc
Olix Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.

Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered

Molecule Type, Application, Route of Administration, and End User and Geography

Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope

Australia, China, Japan, South Korea

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Asia Pacific RNAi Therapeutics Market – By Molecule Type

1.3.2 Asia Pacific RNAi Therapeutics Market – By Application

1.3.3 Asia Pacific RNAi Therapeutics Market – By Route of Administration

1.3.4 Asia Pacific RNAi Therapeutics Market– By End User

1.3.5 Asia Pacific RNAi Therapeutics Market – By Country

2. Asia Pacific RNAi Therapeutics Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific RNAi Therapeutics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 RNAi therapeutics Market - Asia Pacific PEST Analysis

4.3 Expert Opinion

5. Asia Pacific RNAi Therapeutics Market - Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Growing Investments in RNAi Therapies

5.1.2 Rising Prevalence of Chronic Conditions and Infectious Diseases

5.2 Market Restraints

5.2.1 High Cost for RNAi Therapy Development

5.3 Market Opportunities

5.3.1 Significant Number of Pipeline Candidates for Strategic Alliances

5.4 Future Trends

5.4.1 Rising Emphasis on RNA Technologies

5.5 Impact analysis

6. RNAi Therapeutics Market – Asia Pacific Analysis

6.1 Asia Pacific RNAi Therapeutics Market Revenue Forecasts and Analysis

7. Asia Pacific RNAi Therapeutics Market Analysis and Forecasts To 2027 – By Molecule Type

7.1 Overview

7.2 Asia Pacific RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

7.2.1 Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Molecule Type (US$ Mn)

7.3 Small Interfering RNAs (siRNA)

7.3.1 Overview

7.3.2 Asia Pacific Small Interfering RNAs (siRNA) Market Revenue and Forecast to 2027 (US$ Mn)

7.4 MicroRNA (miRNA)

7.4.1 Overview

7.4.2 Asia Pacific MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

8. Asia Pacific RNAi therapeutics Market Analysis and Forecasts To 2027 – By Application

8.1 Overview

8.2 Asia Pacific RNAi therapeutics Market, By Application 2019 & 2027 (%)

8.2.1 Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Application (US$ Mn)

8.3 Genetic Disorders

8.3.1 Overview

8.3.2 Asia Pacific Genetic Disorders Market Revenue and Forecast to 2027 (US$ Mn)

8.4 Oncology

8.4.1 Overview

8.4.2 Asia Pacific Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

8.5 Neurodegenerative Disorders

8.5.1 Overview

8.5.2 Asia Pacific Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.6 Cardiovascular Disorders

8.6.1 Overview

8.6.2 Asia Pacific Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.7 Respiratory Disorders

8.7.1 Overview

8.7.2 Asia Pacific Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

8.8 Infectious Diseases

8.8.1 Overview

8.8.2 Asia Pacific Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.9 Renal Diseases

8.9.1 Overview

8.9.2 Asia Pacific Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

8.10 Other Disorders

8.10.1 Overview

8.10.2 Asia Pacific Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

9. Asia Pacific RNAi therapeutics Market Analysis and Forecasts To 2027 – By Route of Administration

9.1 Overview

9.2 Asia Pacific RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

9.2.1 Asia Pacific RNAi therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

9.3 Intradermal Injections

9.3.1 Overview

9.3.2 Asia Pacific Intradermal Injections Market Revenue and Forecast to 2027 (US$ Mn)

9.4 Pulmonary Delivery

9.4.1 Overview

9.4.2 Asia Pacific Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

9.5 Intravenous Injections

9.5.1 Overview

9.5.2 Asia Pacific Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.6 Intraperitoneal Injections

9.6.1 Overview

9.6.2 Asia Pacific Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

9.7 Other Route of Administrations

9.7.1 Overview

9.7.2 Asia Pacific Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

10. Asia Pacific RNAi Therapeutics Market Analysis – By End-User

10.1 Overview

10.2 Asia Pacific RNAi Therapeutics Market, By End-User 2019-2027 (%)

10.2.1 Asia Pacific RNAi Therapeutics Market Revenue and Forecasts to 2027, By End-User (US$ Mn)

10.3 Diagnostic Laboratories

10.3.1 Overview

10.3.2 Asia Pacific Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.4 Research and Academic Laboratories

10.4.1 Overview

10.4.2 Asia Pacific Research and Academic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

10.5 Hospitals

10.5.1 Overview

10.5.2 Asia Pacific Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

11. RNAi therapeutics Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1 Asia Pacific: RNAi Therapeutics Market

11.1.1 Overview

11.1.2 Asia Pacific: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

11.1.3 Asia Pacific: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.4 Asia Pacific: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.5 Asia Pacific: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.6 Asia Pacific: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.7 Asia Pacific: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

11.1.8 China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1 China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2 China: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.8.3 China: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.8.4 China RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.8.5 China RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.9 Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1 Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2 Japan: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.9.3 Japan: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.9.4 Japan RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.9.5 Japan RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.10 India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1 India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2 India: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.10.3 India: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.10.4 India RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.10.5 India RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.11 South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.1 South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.11.2 South Korea: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.11.3 South Korea: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.11.4 South Korea RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.11.5 South Korea RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.12 Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.1 Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.12.2 Australia: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.12.3 Australia: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.12.4 Australia RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.12.5 Australia RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

12. Impact of COVID-19 Pandemic on Asia Pacific RNAi therapeutics Market

12.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic

13. Company Profiles

13.1 Benitec Biopharma

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Olix Pharmaceuticals, Inc.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 GlaxoSmithKline plc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Alnylam Pharmaceuticals, Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Arrowhead Pharmaceuticals, Inc

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES

Table 1. Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Molecule Type (US$ Mn)

Table 2. Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 3. Asia Pacific RNAi therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

Table 4. Asia Pacific RNAi Therapeutics Market Revenue and Forecasts To 2027, By End-User (US$ Mn)

Table 5. Asia Pacific RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)

Table 6. Asia Pacific RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 7. Asia Pacific RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 8. Asia Pacific RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 9. China RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 10. China RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11. China RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 12. China RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 13. Japan RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 14. Japan RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 15. Japan RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 16. Japan RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 17. India RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 18. India RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 19. India RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 20. India RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 21. South Korea RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 22. South Korea RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 23. South Korea RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 24. South Korea RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 25. Incidence, Mortality and Prevalence by cancer site, Australia, 2018

Table 26. Australia RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 27. Australia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 28. Australia RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 29. Australia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 30. Glossary of Terms, RNAi Therapeutics Market

LIST OF FIGURES

Figure 1. RNAi Therapeutics Market Segmentation

Figure 2. Asia Pacific RNAi Therapeutics Market Overview

Figure 3. Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market

Figure 4. China is Expected to Show Remarkable Growth During the Forecast Period

Figure 5. Asia Pacific RNAi Therapeutics Market - Leading Country Markets (US$ Mn)

Figure 6. RNAi Therapeutics Market - Asia Pacific PEST Analysis

Figure 7. RNAi Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8. Asia Pacific RNAi Therapeutics Market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9. Asia Pacific RNAi Therapeutics Market, By Molecule Type 2019 & 2027 (%)

Figure 10. Asia Pacific Small Interfering RNAs (siRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11. Asia Pacific MicroRNA (miRNA) Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12. Asia Pacific RNAi therapeutics Market, By Application 2019 & 2027 (%)

Figure 13. Asia Pacific Genetic Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14. Asia Pacific Oncology Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15. Asia Pacific Neurodegenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16. Asia Pacific Cardiovascular Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17. Asia Pacific Respiratory Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18. Asia Pacific Infectious Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19. Asia Pacific Renal Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20. Asia Pacific Other Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21. Asia Pacific RNAi therapeutics Market, By Route of Administration 2019 & 2027 (%)

Figure 22. Asia Pacific Intradermal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23. Asia Pacific Pulmonary Delivery Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24. Asia Pacific Intravenous Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25. Asia Pacific Intraperitoneal Injections Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26. Asia Pacific Other Route of Administrations Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 27. Asia Pacific RNAi Therapeutics Market, by End-User 2019 & 2027 (%)

Figure 28. Asia Pacific Diagnostic Laboratories Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 29. Asia Pacific Research and Academic Laboratories Mark et Revenue and Forecasts to 2027 (US$ Mn)

Figure 30. Asia Pacific Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 31. Asia Pacific: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 32. Asia Pacific RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 33. China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 34. Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 35. India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 36. South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 37. Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 38. Impact of COVID-19 Pandemic in Asia-Pacific Country Markets

Benitec Biopharma
Olix Pharmaceuticals, Inc.
GlaxoSmithKline plc
Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
Validates and strengthens in-house secondary research findings
Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

Industry participants: VPs, business development managers, market intelligence managers and national sales managers
Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Asia Pacific RNAi Therapeutics Market Analysis and Opportunities by 2027

The Asia Pacific RNAi therapeutics market is expected to reach US$ 218.64 million by 2027 from US$ 107.63 million in 2019. The market is estimated to grow at a CAGR of 9.3% from 2020 to 2027.

Rest of Asia Pacific RNAi Therapeutics Market, Revenue, and Forecast to 2027 (US$ Million)

Asia Pacific RNAi Therapeutics Market Segmentation

By Molecule Type

By Route of Administration

By Application

By End User

By Country

Company Profiles

Report Coverage

Segment Covered

Regional Scope

Country Scope

Infectious Disease In vitro Diagnostics Market

Donor Blood Components Market

Aesthetic Injectable Devices Market

ECG Monitoring Equipment Market

Prescription Drugs Market

Regenerative Dentistry Market

Wound Closure Devices Market

Cell and Gene Therapy Contract Development and Manufacturing Organization Market